Savvy Advisors Inc. Purchases 5,236 Shares of AbbVie Inc. $ABBV

Savvy Advisors Inc. lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 21.2% in the 3rd quarter, Holdings Channel.com reports. The fund owned 29,922 shares of the company’s stock after buying an additional 5,236 shares during the quarter. Savvy Advisors Inc.’s holdings in AbbVie were worth $6,928,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie in the second quarter worth $26,000. Spurstone Advisory Services LLC purchased a new position in AbbVie in the 2nd quarter worth about $28,000. Financial Gravity Companies Inc. bought a new position in AbbVie during the 2nd quarter valued at about $36,000. Delos Wealth Advisors LLC bought a new stake in shares of AbbVie in the second quarter worth approximately $39,000. Finally, Cloud Capital Management LLC purchased a new position in shares of AbbVie during the third quarter valued at approximately $53,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ABBV has been the topic of several research reports. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Evercore lowered their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Guggenheim lifted their price objective on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Berenberg Bank set a $275.00 target price on AbbVie in a report on Tuesday, January 20th. Finally, UBS Group dropped their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $251.00.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record Q4 net sales and upbeat guidance reinforce AbbVie’s diversified growth story (Skyrizi/Rinvoq strength and overall revenue beat), supporting longer-term earnings visibility. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and $250 price target following the strong quarter, signaling continued analyst confidence that could support the share price. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: AbbVie’s real‑world migraine (ubrogepant) study could expand market potential for its acute migraine franchise, a constructive long-term revenue opportunity if outcomes are favorable. AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
• Neutral Sentiment: Clinical program update: AbbVie posted a Phase 2 elezanumab study update in acute cervical spinal cord injury — relevant for pipeline upside but data are early and timing/impact remain uncertain. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury
• Neutral Sentiment: Operational repositioning: coverage suggests AbbVie is reshaping U.S. operations with Medicaid concessions to prioritize growth categories — could ease payer tensions but may compress near-term margins. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus
• Negative Sentiment: AbbVie sued HHS over CMS selecting Botox for Medicare price cuts under the Inflation Reduction Act — the dispute highlights material regulatory risk to Botox revenue and creates legal uncertainty. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Evercore ISI trimmed its price target modestly (while keeping Outperform), and broader analyst chatter highlights valuation/forecast risk — small downgrades can pressure sentiment after a rally. Evercore ISI Cuts AbbVie Inc. (ABBV) PT
• Negative Sentiment: Competitive pressure: heavy TV ad spending for J&J’s Tremfya (and continued promotion of rivals) raises marketing intensity in immunology, which could cap near‑term share gains for Rinvoq/Skyrizi. J&J’s Tremfya roars into 2026 with massive TV ad spend, trailed by AbbVie’s Rinvoq and Skyrizi

AbbVie Stock Performance

NYSE ABBV opened at $220.74 on Thursday. The business’s fifty day moving average is $223.47 and its 200 day moving average is $220.29. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a market capitalization of $390.12 billion, a PE ratio of 93.53, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the prior year, the business posted $2.16 earnings per share. The business’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.